At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immunological disorders. Our goal is to provide patients and caregivers with more efficacious therapies that significantly reduce treatment burden. Our vision is embodied in our current focus – the development of a groundbreaking anti-TSLP therapy with best-in-class potential. We are a San Francisco Bay area-based clinical stage biopharma company with additional operations in London, UK. The Aiolos team is comprised of seasoned drug developers, who have successfully developed and launched products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more. As we grow, we will look to add like-minded individuals to our team - those committed to the goal of providing a meaningful difference in the lives of patients suffering from respiratory illnesses and other immune disorders.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $245M
Founded date: 2023
Investors 3
| Date | Name | Website |
| 05.12.2023 | Forbion | forbion.co... |
| 25.10.2023 | Sofinnova ... | sofinnova.... |
| 26.10.2023 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.10.2023 | Series A | $245M | - |
Mentions in press and media 18
| Date | Title | Description |
| 03.03.2025 | Forbion Expands US Presence with the Appointment of Regina Salvat, PhD, as Principal in the Boston Office | Naarden, The Netherlands - 03 March 2025 - Forbion is pleased to announce the appointment of Regina Salvat, PhD, as Principal in our Boston office. This strategic hire underscores our commitment to strengthening our presence in the United S... |
| 11.02.2025 | Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors | - Tosh, formerly President of Idorsia and Chief Operating Officer of ChemoCentryx, brings more than 20 years of leadership experience from global pharma and biotech companies - Khurem Farooq, Chief Executive Officer of Verdiva Bio and forme... |
| 12.01.2025 | European Tech Landscape: A Surge of Innovation and Investment | The European tech scene is buzzing. A recent wave of funding, acquisitions, and innovative breakthroughs paints a vibrant picture of the continent's entrepreneurial spirit. This week alone, over 40 tech funding deals topped €1.3 billion. Th... |
| 10.01.2025 | Verdiva Bio launches with $411M Series A raise for next-gen oral and injectable treatments for obesity | Pharmatech company Verdiva Bio launched this week with an eye-watering $411 million Series A. Focused on developing innovative therapies for obesity and other cardiometabolic disorders, Verdiva Bio is creating next-generation oral and injec... |
| 09.01.2025 | Forbion Co-Leads over $410M Series A Financing to Launch Verdiva Bio, a Clinical-Stage Cardiometabolic Company Advancing Next-Generation Therapies | - Co-founded by Khurem Farooq and former members of Aiolos Bio team to develop broad portfolio of oral and injectable treatments for obesity, cardiometabolic disorders, and related complications - Forbion played an instrumental role in the ... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 15.10.2024 | Forbion raises in excess of €2 billion for two new funds | • Forbion’s largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2 billion and Forbion Ventures Fund VII raising €890 million • Assets under management now at €5 billion • Fundraising follows strong performan... |
| 21.05.2024 | Forbion leads $65 million Series A Financing of Progentos Therapeutics | • Forbion led the Series A financing to support the development of Progentos’ lead program in multiple sclerosis along with additional pipeline programs • Progentos Therapeutics is developing novel small molecules to induce de-novo remyelin... |
| 16.05.2024 | enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder c... |
Show more